Tumor mass and dissemination represent major limiting factors to successful cancer therapies. Surgery, chemotherapy and radiation therapy are conventionally used to reduce tumors, although with variable success. Surgery can be efficient in removing the primary tumor mass, but has limited clinical utility with disseminated metastases. Radiation therapy can also affect some responsive tumors, but is difficult to apply to disseminated metastases. On the other hand, chemotherapy reduces the mass of metastases, at least in some cases, but is associated with major side-effects for patients, including strong immunosuppression. 1 For these reasons, it is necessary to develop new approaches for cancer treatment, based on different principles, exhibiting low toxicity and high efficiency in eradicating disseminated lesions. In this respect, immunotherapy and anti-angiogenic therapy of tumors appear very promising. Here, we discuss why the combination of both approaches may result in a significant improvement in the long-lasting control of disseminated neoplasia.
There is a strong rationale behind the application of immunotherapy to cancer. First, it is now clear that many tumor types express proteins that are either qualitatively or quantitatively different from their normal tissue counterparts, and that can be recognized by autologous T lymphocytes as tumor associated antigens (TAA). 2 Preclinical studies have established the efficacy of antigenspecific immunotherapy of cancer, 3 while recent clinical trials show that vaccination with melanoma-derived TAAs leads to a significant number of clinical responses in patients. 4, 5 Second, intrinsic biologic properties of T lymphocytes make them an ideal weapon to fight disseminated cancer cells. Activated T cells recirculate in the body, extravasate into tissues and stop where they find their cognate peptide-MHC complexes, which trigger effector functions. 6 Moreover, the establishment of immunological memory following vaccination with TAAs would ensure the long-lasting persistence of antitumor T cells, providing a surveillance system on possible tumor relapse.
The results of most preclinical and some clinical studies, however, indicate that the efficacy of tumor-specific T cells is inversely related to the overall tumor mass. Some studies have proposed that this phenomenon may be due to an increased secretion of immunosuppressive cytokines (eg IL-10, TGF-␤) by growing tumors, or to the expression of cytotoxic molecules for T cells (FAS-L). 7 Moreover, tumor-specific CTLs, expanded by tumor vaccines, appear to exert their cytolytic activity for a limited time. Therefore, when the number of tumor cells exceeds the cytolytic potential of CTLs, some tumor cells will escape killing and start to grow again, resulting in tumor relapse. 8 Subsequent vaccination boosts are required to re-expand antitumor CTLs, that however cannot eradicate the relapsed tumor. 8 As a consequence of these limitations, immunotherapy is at present only envisaged to treat patients bearing a minimal residual disease, large enough to be eradicated by a single wave of CTLs. The efficacy of cancer immunotherapy, however, could be improved by association with strategies that decrease tumor masses and, unlike chemotherapy, are not immunosuppressive.
Targeting neo-angiogenesis to kill tumor cells appears to be one of the most promising therapeutic approaches for cancer. First, since tumor-associated vascular endothelium is composed of nontransformed cells, it can be targeted by repeated treatments, without facing the danger of selecting resistant variants. 9 Second, by destroying a relatively low number of tumor vessels, it should be possible to destroy a large number of tumor cells, which rely on that blood support to thrive. 10 Third, anti-angiogenic compounds should efficiently target disseminated metastases. Pre-clinical studies have shown the potential antitumor effects of several anti-angiogenic compounds. Treatment of mice bearing large tumors with endostatin and/or angiostatin, two potent anti-angiogenic polypeptides derived from collagen XVIII and plasminogen respectively, indeed induces tumor regression as well as dormancy. 9 The C-X-C chemokines IP-10, Mig, PF-4 and Gro-beta also have strong inhibitory effects on tumor growth, mainly due to their anti-angiogenic activity. Although their mechanisms of action on tumor endothelium are not completely understood, they have angiostatic effects and inhibit tumor growth by causing hemorrhagic necrosis.
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TNF-␣ is another cytokine exerting potent antitumor effects, mainly by inducing endothelial cell damage and a shift to a pro-coagulant state, finally resulting in massive hemorrhagic necrosis. Remarkably, normal vessels close to the tumor are not affected by TNF, indicating that this cytokine can distinguish the vasculature of normal tissues from that of tumors. This selectivity would be due to the fact that TNF (together with IFN␥) inhibits the activation of the endothelial cell ␣ v ␤ 3 integrin, 12 an adhesion receptor expressed by endothelial cells of angiogenic but not quiescent vessels, and critical for the survival of endothelial cells. 13 In spite of their efficacy in reducing vascularized tumor masses, it is still questionable whether these antiangiogenic compounds can eliminate all neoplastic cells that may persist in the organism without needing an organized vascular tree. Moreover, since tumors often relapse upon withdrawal of the anti-angiogenic compounds, anti-angiogenic therapy implies a prolonged administration of the compound, 9 increasing the risk of side-effects on physiological vascularization processes. Finally, while systemic treatment with anti-angiogenic compounds reduce the tumor mass, there is no evidence for the concomitant induction of a protective antitumor immunity, which could act in synergy to keep tumor growth under control. 9 In the light of these considerations, it is conceivable that the combination of a short course of anti-angiogenic therapy, which efficiently shrinks the tumor mass, with the induction of a tumor-specific immunity, which eliminates the residual tumor cells, would improve the therapeutic outcome. The clinical use of anti-angiogenic compounds could be further improved by targeting their action to the tumor site. This would improve, for instance, the clinical use of TNF, which is so far limited to loco-regional treatments because of high systemic toxicity. Molecules that can selectively target structures associated with tumor vasculature, such as peptides that bind the ␣ v ␤ 3 integrin 14 or mAbs that bind an angiogenesisassociated fibronectin isoform, 15 may serve as vehicles to increase the therapeutic indexes of TNF and other antiangiogenic factors, by delivering them to the tumor vasculature.
In conclusion, a therapy that impairs the function of tumor-associated vessel without causing immunosuppression would provide an attractive approach to reducing large tumor masses before immunotherapy. Following tumor reduction, active or adoptive immunotherapy would then find the appropriate conditions to cope with the residual disease, leading possibly to complete eradication of residual disseminated tumor cells from the patient.
